CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer

By sjmartinez • March 23, 2024

Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, Li R, Patel TS, Man S, Yean CE, Abascal J, Huang Z, Ong SL, Krysan K, Dubinett SM, Liu B. CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Rep Med. 2024 Mar 19:101479. doi: 10.1016/j.xcrm.2024.101479. Epub ahead of print. PMID: 38518770.

Tags: Checkpoint blockade, CXCL10, CXCL9, CXCR3, dendritic cells, Fellow, Hematology/Oncology, immunosuppression, in situ vaccination, NSCLC, Publications, Pulmonary, Critical Care & Sleep Medicine, Resident, systemic immunity, T cells, Veterans Administration

Related Posts

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study

LeVee A, Santos B, Wong M, Ruel N, Schmolze D, Kang I, Tsai K, Mortimer J, McArthur H. Predictors of pathologic complete response in early-stage[...]

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Piotrowska Z, Goldberg SB, Goldman JW, de Langen AJ, Le X, Okamoto I, Riess JW, Yu HA, Nishino K, Novello S, Ponce S, Ambrose H,[...]

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]